Diastereoselective synthesis of alpha-aryl substituted LnDOTA chelates from achiral starting materials by deracemization under mild conditions

28 July 2023, Version 2
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Substituted derivatives of the DOTA framework are of general interest to alter chelate properties and facilitate conjugation of chelates to other molecular structures. However, the scope of substituents that can be introduced into the alpha-position has traditionally been limited by the availability of a suitable enantiopure starting materials to facilitate a stereoselective synthesis. Tetra-substituted DOTA derivatives with phenyl and benzoate substituents in the alpha-position were prepared. Initial syntheses used enantiopure starting materials but did not afford enantiopure products. This indicates that integrity of the stereocentres was not preserved during synthesis, despite the homo-chiral diastereoisomer being the major reaction product. The homochiral diastereoisomer could be produced as the major or sole reaction product when starting from racemic or even achiral materials. Deracemization was found to occur during chelation through formation of an enolate stabilized by the aryl substituent. This general ability of aryl groups to enable deracemization greatly increases the range of substituents that can be introduced into DOTA-type ligands with diastereochemical selectivity.

Keywords

Diastereoisomeric resolution
DOTA-derivatives
Enolization
Multivariate analysis Stereoselective synthesis

Supplementary materials

Title
Description
Actions
Title
Additional Figures and experimental details
Description
Additional Figures and experimental details
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.